Supriya Lifescience Limited has released its investor presentation for the second quarter and first half of the financial year 2027. The presentation highlights the company’s financial performance, including revenue, EBITDA, PBT, and PAT for both the quarterly and half-yearly periods. It also provides insights into the business mix revenue contribution by region and therapy, alongside historical financial performance and future outlook.
Supriya Lifescience Presents Q2 and H1 FY27 Results
Supriya Lifescience Limited has submitted its Investor Presentation for the quarter and half-year ended September 30, 2026. The document provides a comprehensive overview of the company’s financial performance and operational highlights.
Financial Highlights
For Q2 FY27, the company reported Revenue of INR 2,063.0 Mn, a 3.2% Year-on-Year (YoY) increase. EBITDA stood at INR 454.0 Mn (down 37.5% YoY), PBT at INR 377.8 Mn (down 44.7% YoY), and PAT at INR 292.5 Mn (down 42.0% YoY).
The first half of FY27 (H1 FY27) saw Revenue of INR 3,960.4 Mn, an increase of 14.8% YoY. EBITDA was reported at INR 928.6 Mn (down 25.3% YoY), PBT at INR 785.7 Mn (down 32.1% YoY), and PAT at INR 532.9 Mn (down 37.5% YoY).
Revenue Contribution and Margins
The business mix revenue contribution by region indicates significant presence in Asia and Europe, with LATAM, North America, and Others also contributing. The presentation also details the breakdown by therapy, showing ‘Anesthetic’ as a leading segment, followed by ‘Vitamins’, ‘Anti-Histamine’, and ‘Anti-Asthmatic’.
EBITDA Margins for Q2 FY27 stood at 22.0%, and PAT Margins were 14.2%. For H1 FY27, EBITDA Margins were 23.4%, and PAT Margins were 13.5%.
Balance Sheet and Operational Overview
The Balance Sheet as of September 26 shows Total Assets of INR 14,217 Mn and Total Equity and Liabilities of INR 14,217 Mn. The company’s business overview highlights a global leader in several therapeutic areas, with over 40+ APIs, a presence in 120+ Countries, and a manufacturing facility spread across 35,000 sq.mts.
Future Outlook and Strategy
The future outlook focuses on R&D centres, CMO/CDMO space, new markets, and capacity enhancement. Supriya Lifescience is expanding its API customer base across Japan, EU, and US, and is pursuing regulatory approvals in EU and US. The company is also investing in capacity enhancement with new production blocks and lines.
Source: BSE
